Following Lilly's Emgality (Galcanezumab), Teva's Ajovy (Fremanezumab) were released in Korea as a new medicine for migraine prevention.

Attention is focusing on whether CGRP (calcitonin gene-related peptide) drugs, which have entered the domestic migraine treatment market without suitable treatments, will become popular.

Aimovig is not yet authorized in Korea. On Wednesday, the MFDS approved Teva Handok's migraine prevention drug Ajovy. It is the second CGRP drug after Lilly's Emgality. Emgality was granted permission in September 2019. It was released in December of that year as non reimbursed drug.

Amgen is reportedly aiming for another CGRP drug, Aimovig (Erenumab), to